抗糖尿病药物甲福尔明的辐射保护作用
Silvia Siteni1, Summer Barron1, Krishna Luitel1
1Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
PloS one
|July 23, 2024
概括
甲胺通过增强DNA修复和细胞解毒途径来证明其辐射保护作用. 这种常见的糖尿病药物在临床前模型中显著提高了辐射暴露后的生存率.
科学领域:
- 辐射生物学 辐射生物学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 甲胺是一种广泛用于治疗2型糖尿病的药物,以其抗血糖作用而闻名.
- 甲福明表现出超出葡萄糖调节的各种度依赖的类作用.
研究的目的:
- 为了研究甲胺的潜在辐射保护作用.
- 在细胞和动物模型中阐明梅特福林放射电阻背后的机制.
主要方法:
- 在人体纤维细胞暴露于辐射的体外研究.
- 在体内研究中,使用预先用甲福明治疗并接受辐射 (全身辐射和模拟银河系宇宙射线) 的小鼠.
- 对DNA损伤,DNA修复机制和基因表达的评估 (SOD1,OGG1).
主要成果:
- 甲胺增强了DNA损伤的修复和SOD1表达在体外.
- 在暴露于辐射和GCRsim的小鼠中,甲胺预处理减少了DNA损伤和微核的形成.
- 在10Gy照射和高调的OGG1表达后,甲胺增加了37%的生存率.
结论:
- 在体外和体外模型中,甲胺表现出显著的辐射保护性质.
- 这种保护作用似乎是由参与细胞解毒的基因表达的间接调节所介导的.
- 甲胺在辐射保护中的作用需要进一步研究潜在的治疗应用.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
186
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
186
Electron Transport Chain: Complex I and II
12.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.7K
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180


